Why the study?
Clinical use of doxorubicin is limited by cardiotoxicity leading to heart failure, prompting investigation into the role of endothelial cells as targets for detection, management, and prevention.
The endothelium represents a novel target for improving the detection, management, and prevention of doxorubicin-induced cardiomyopathy.
Answers are grounded in this paper and cite their sources.
Endothelial monitoring may aid doxorubicin cardiomyopathy detection; leaves open interventional trials before adoption.
The clinical use of doxorubicin in cancer is limited by cardiotoxic effects that can lead to heart failure. Whereas earlier work focused on the direct impact of doxorubicin on cardiomyocytes, recent studies have turned to the endothelium, because doxorubicin-damaged endothelial cells can trigger the development and progression of cardiomyopathy by decreasing the release and activity of key endothelial factors and inducing endothelial cell death. Thus, the endothelium represents a novel target for improving the detection, management, and prevention of doxorubicin-induced cardiomyopathy.
No takes yet. Share an insight, caveat, or question.
Luu et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: